1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
ResMed Inc.

ResMed Inc.

RMD.AX
ResMed Inc.AU flagAustralian Securities Exchange
25.84
AUD
-0.18
- -
37.48BMarket Cap
ResMed Inc.
RMD.AX
(Australian Securities Exchange)

Recent

price

25.84

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.72
0.82
0.94
1.06
1.1
1.2
1.31
1.46
1.64
1.82
2.05
2.2
2.45
2.88
3.19
3.51
3.8
Revenue per Share
0.13
0.15
0.17
0.21
0.24
0.25
0.25
0.24
0.22
0.28
0.43
0.33
0.53
0.61
0.69
0.95
1.04
Basic EPS, GAAP
0.08
0.14
0.22
0.23
0.22
0.22
0.34
0.24
0.3
0.27
0.48
0.43
0.13
0.38
0.87
1.13
1.19
Free Cash Flow per Basic Share
- -
- -
- -
0.07
0.1
0.11
0.12
0.13
0.14
0.15
0.16
0.16
0.17
0.18
0.19
0.21
0.23
Dividend per Share
0.59
0.73
0.94
1.1
1.26
1.41
1.54
1.64
1.7
1.7
1.96
2.12
2.47
2.9
3.4
4.15
4.77
Book Value per Share
0.7
0.95
0.89
0.9
1.01
0.91
0.24
0.45
0.54
-0.21
0.11
0.39
0.74
0.55
1.04
1.67
2.07
Tangible Book Value per Share
1,509
1,525
1,459
1,430
1,415
1,405
1,402
1,414
1,428
1,431
1,443
1,453
1,461
1,468
1,470
1,467
1,459
Basic Weighted Avg Shares
1,092
1,243
1,369
1,514
1,555
1,679
1,839
2,067
2,340
2,607
2,957
3,197
3,578
4,223
4,685
5,146
5,538
Sales/Revenue/Turnover
22.28
21.47
21.51
23.43
26.46
24.38
23.7
22.1
23.94
24.4
27.36
28.54
28.01
27.28
29.54
32.79
34.6
Operating Margin (%)
62
71
86
78
73
73
87
112
120
151
181
192
194
198
216
236
263
Depreciation Expense
190
227
255
307
345
353
352
342
316
405
622
475
779
898
1,021
1,401
1,520
Net Income, GAAP
27.06
25.26
23.23
20.25
19.9
19.05
19.83
18.26
39.46
22.02
15.2
46.3
18.85
18.53
19.28
16.5
20.16
Effective Tax Rate (%)
17.4
18.26
18.62
20.28
22.2
21.02
19.17
16.56
13.49
15.52
21.02
14.84
21.78
21.25
21.79
27.22
27.44
Profit Margin (%)
673
1,084
1,108
875
1,287
1,141
782
1,284
554
589
921
663
1,242
1,609
1,447
2,486
2,713
Working Capital
- -
100
251
1
301
301
873
1,079
270
1,259
1,266
758
886
1,548
839
811
554
LT Debt
1,288
1,731
1,608
1,611
1,758
1,587
1,695
1,960
2,059
2,072
2,497
2,886
3,361
4,130
4,864
5,968
6,492
Total Equity
12.7
12.22
12.13
14.74
16.38
16.63
14.51
12.48
12.16
16.76
18.86
12.5
19.58
18.57
19.21
21.99
21.91
Return on Invested Capital (%)
20.6
20.57
18.27
17.86
17.69
16.41
12.88
10.86
10.89
13.48
16.73
12.17
18.98
18.06
18.08
21.89
21.07
Return on Capital (%)
24.05
22.72
20.55
20.86
20.56
18.78
17.04
15.29
13.29
16.62
23.59
16.05
23.29
22.82
22.08
25.3
23.86
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
290
290
289
LT Borrowings
409
404
404
LT Finance Leases
148
154
150
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
146
146
145
Market Capitalization
39,791
35,097
32,372

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
3,626
3,819
4,064
Cash, Cash Equivalents & STI
1,384
1,417
1,661
Accounts Receivable, Net
907
986
999
Inventories
946
922
912
Total Current Liabilities
1,256
1,248
1,351
Payables & Accruals
798
782
883
ST Debt
290
290
289
Deferred Revenue
168
176
179

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.4%
19.08%
22.69%
Free Cash Flow
38.81%
53.1%
28.34%
Net Income, GAAP
17.77%
21.34%
37.2%
Sales/Revenue/Turnover
11.88%
11.77%
9.84%
Total Cash Common Dividend
7.09%
6.73%
10.12%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,102
1,163
1,197
1,223
4,685
2025
1,225
1,282
1,292
1,348
5,146
2026
1,336
1,423
1,431
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.14
0.2
0.2
0.69
2025
0.21
0.23
0.25
0.26
0.95
2026
- -
0.27
0.27
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.05
0.05
0.05
0.19
2025
0.05
0.05
0.05
0.05
0.21
2026
- -
0.06
0.06
- -
- -
Similar Companies
Lucira Health, Inc. (LHDX)
Broncus Holding Corporation (BRNHF)
Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ)
GigCapital5, Inc. (GIA-WT)
NewCardio, Inc. (NWCI)
Senzime AB (publ) (SNZZF)
Business
ResMed Inc. (NYSE: RMD, ASX: RMD) develops, manufactures and commercializes cloud-connected medical devices and digital health solutions for sleep-disordered breathing, chronic obstructive pulmonary disease (COPD) and other respiratory conditions; core offerings include CPAP and APAP sleep therapy devices such as the AirSense series, bilevel devices and ventilators including the Astral and Lumis series, masks and accessories encompassing the AirFit and AirTouch lines like the recently launched AirTouch N30i nasal mask with fabric cushion, patient engagement platforms such as myAir with new Streaks feature for therapy tracking, provider monitoring software including AirView, and SaaS platforms for out-of-hospital care via subsidiaries from prior acquisitions like Brightree and MEDIFOX DAN. The company operates through Sleep and Respiratory Care and Software-as-a-Service segments, serving patients, healthcare providers, home medical equipment suppliers and caregivers in over 140 countries with significant presence in North America, Europe and Asia-Pacific. Founded in 1989 in Sydney, Australia, by Dr. Peter Farrell to commercialize CPAP technology, ResMed established U.S. headquarters in San Diego, California, following its 1992 office opening and 1994 incorporation there. ResMed pursues growth through strategic acquisitions and product innovation; it acquired VirtuOx in May 2025, an independent diagnostic testing facility enhancing at-home sleep, respiratory and cardiac diagnostics to streamline pathways from evaluation to therapy and expand virtual care capabilities, with VirtuOx operating as a wholly owned subsidiary. Earlier moves include the 2022 acquisition of MEDIFOX DAN for about $1 billion to bolster European SaaS for out-of-hospital care and the 2016 purchase of Brightree for $800 million to enter U.S. post-acute SaaS. Recent developments feature launches of the AirFit F40 mask, Ectosense and NightOwl home sleep test technologies, and the first-generation AI product Dawn, alongside initiation of the Sleep Institute for global sleep health insights. In fiscal 2025 first-quarter results announced November 2025, ResMed reports nine percent headline revenue growth, 280 basis points of non-GAAP gross margin expansion and double-digit profit increase, driven by hardware, software and digital innovation amid market share gains from competitor recalls.

Company News

APIChat

  • globenewswire.com

    Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

  • globenewswire.com

    Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy